MRK Merck announces initial access plans for alimatravir, an investigational once-monthly oral hiv pre-exposure prophylaxis in phase 3 devel
MRK Merck announces initial access plans for alimatravir, an investigational once-monthly oral hiv pre-exposure prophylaxis in phase 3 development